Israel Desks - February 2020 Edition

7 cannabis company with a US$ 1.7 Billion market cap on NASDAQ, to import cannabis to Israel - the first legal commercial cannabis import deal in Israel. Also inJanuary, BOLPharma,oneof Israel’s largest and leadingmanufacturer of pharma GMP certified medical cannabis products, brokered a strategic partnership with Astral Health, a specialist import and distribution company and subsidiary of LYPHE Group, to ship medical cannabis to treat patients in the UK with treatment-resistant epilepsy. Challenges include new layers of regulation that come with incremental legalization – such as securities and FDA compliance,” adds Kittay, “while the opportunities presented by topicals and nutraceuticals are avoiding real and perceived health stigmas and issues associated with smoking or vaping cannabis, while at the same time availing consumers to perceived health benefits.” “Themain challenge at themoment is regulation,”agreesBerkovits. ״ If during 2020 export is permitted, it will certainly cause a wave of new development in the medical cannabis industry in Israel.” “While the Israeli regulatory regime is still developing (and export regulations have been unfortunately delayed), the Israeli ecosystem in this space is viewed as more advanced than most others,” adds Selinger. Israel is certainly on the right track. In January 2019, the Israeli cabinet approved the export of processed and finished medical cannabis products, which include medical cannabis products such as packed flowers, oils, capsules, and medicated drops. For a producer to be allowed to export cannabis products, it must be approved by the Israeli Ministry of Health, the Israel Police Department, have Good Manufacturing Practices (GMP) and Generalized System of Preferences (GSP) certifications, and the applicable Regulatory Hurdles to Navigate Israel joins Canada, Australia and Netherlands in right to export medical cannabis